Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions, Inc. (NASDAQ: BLFS) is a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. News about BLFS often centers on how its biopreservation media, CellSeal vials, hPL products, and related cell processing tools are used in clinical trials and commercial CGT therapies, as well as on portfolio changes and strategic transactions.
Investors and industry followers can use this page to track BioLife’s announcements on quarterly and annual financial results, including updates on Cell Processing revenue and the performance of its biopreservation media franchise. The company regularly reports on the contribution of customers with approved therapies, the extent of clinical trial adoption in the United States, and its use of GAAP and non-GAAP measures such as adjusted gross margin and adjusted EBITDA.
BioLife’s news flow also includes updates on portfolio streamlining and strategic moves, such as the divestiture of its evo cold chain logistics subsidiary and earlier sales of Global Cooling, SciSafe, and Custom Biogenic Systems, as well as acquisitions and investments like the PanTHERA CryoSolutions IRI cryopreservation technology and the strategic investment in Pluristyx. These items illustrate how the company is focusing on its core cell processing business while adding scientific capabilities and adjacencies.
In addition, BioLife issues press releases on corporate developments such as the opening of the Aby J. Mathew Center for Biopreservation Excellence in Bothell, Washington, and participation in healthcare and small- and mid-cap investor conferences. For readers following the CGT supply chain, this news page provides a centralized view of BioLife’s operational updates, clinical adoption metrics, strategic transactions, and investor communications over time.
BioLife Solutions (NASDAQ: BLFS), a leading bioproduction products supplier for cell and gene therapy, has made a $2 million strategic investment in Pluristyx through convertible notes. The investment includes a board observer seat and potential future acquisition rights.
Pluristyx, a Seattle-based company, develops innovative induced pluripotent stem cell (iPSC) products for cell therapy developers. The investment aligns with BioLife's strategy of exploring biological assays as a product portfolio expansion, following similar investments in Sexton and PanTHERA.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, will release its second quarter 2025 financial results after market close on Thursday, August 7, 2025.
The company will host a conference call and webcast at 4:30 PM ET where management will discuss financial results and provide a business update. Investors can access the webcast through BioLife's website or join via phone using the provided toll-free numbers.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, has announced its participation in five upcoming investor conferences in May and June 2025. The company will attend the Craig-Hallum Institutional Investor Conference (May 28, Minneapolis), Benchmark Healthcare House Call Virtual Conference (May 29), Jefferies Global Life Sciences Conference (June 3-5, New York), Wolfe Research Small & Mid-Cap Conference (June 5, New York), and Northland Growth Conference (June 25, Virtual).
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, has provided updated dial-in information for their earnings call scheduled for today at 4:30pm ET. U.S. participants can dial 1-833-630-0431, while international callers should use 1-412-317-1808.
BioLife Solutions specializes in providing solutions that maintain the health and function of biological materials throughout the collection, development, manufacturing, and distribution processes, supporting the commercialization of new therapies in the CGT market.
BioLife Solutions, a key player in the cell and gene therapy (CGT) market, has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company, which specializes in bioproduction products and services, will release its Q1 2025 results after market close on Thursday, May 8, 2025.
The company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) on the same day. Management will present the financial results and provide a business update. Investors and interested parties can access the webcast through the company's Investor Relations page or join via phone using the toll-free numbers: 1-877-344-7529 (domestic) or 1-412-317-0088 (international).
A replay of the webcast will be available approximately two hours after the call and will remain accessible on the investor relations website for 90 days.
BioLife Solutions (NASDAQ: BLFS) has acquired PanTHERA CryoSolutions, strengthening its position in the cell and gene therapy (CGT) market. The acquisition focuses on PanTHERA's proprietary Ice Recrystallization Inhibitor (IRI) technology for cryopreservation solutions.
The transaction involves $9.3 million in cash and 241,355 BLFS shares for the remaining 90% ownership, with potential additional payments of up to $7.2 million in stock based on milestone achievements over three years. This marks BioLife's second acquisition from its Bioproduction Innovation Accelerator program.
PanTHERA's next-generation formulations, expected to launch within 18 months, aim to provide superior cryopreservation outcomes, reduce DMSO concentrations, and decrease liquid nitrogen requirements in cold chain logistics and storage.
BioLife Solutions (NASDAQ: BLFS), a leading supplier of bioproduction tools for the cell and gene therapy market, has appointed Cathy Coste to its board of directors, expanding the board to seven members. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who remains a director and committee member.
Coste brings over 40 years of senior executive experience, including 30+ years at Deloitte where she served as a senior partner and life sciences industry executive leader. She has worked with more than two dozen life sciences companies and currently serves as audit committee chair for Biomerica, Minerva Surgical, and Renalytix plc.
The appointment comes as BioLife completes its transition to a pure-play enabler of cell and gene therapies, positioning the company for revenue growth and sustained profitability.
BioLife Solutions (BLFS) reported strong Q4 and full-year 2024 results, with notable growth in its Cell Processing segment. Q4 total revenue reached $22.7 million, up 31% year-over-year, driven by Cell Processing revenue of $20.3 million, representing a 37% increase.
The company achieved a GAAP gross margin of 60% and adjusted EBITDA of $4.0 million (18% of revenue) in Q4. Full-year 2024 revenue totaled $82.3 million, an 8% increase from 2023. The company strengthened its financial position by divesting non-core businesses, including SciSafe and CBS, resulting in a cash position exceeding $100 million.
Looking ahead, BioLife projects 2025 revenue guidance of $95.5-99.0 million, representing 16-20% growth. The Cell Processing platform is expected to grow 18-21% to $86.5-89.0 million. The company's biopreservation media is now embedded in 17 approved cell and gene therapies, with 8 additional approvals anticipated in the next 12 months.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, has scheduled its fourth quarter and full year 2024 financial results release for March 3, 2025, before market open.
The company will host a conference call and webcast at 8:00am ET (5:00am PT) on the same day, where management will present financial results and provide a business update. Investors can access the webcast through BioLife's website or join via phone using the toll-free number 1-833-630-0431 (international: 1-412-317-1808). A replay will be available approximately two hours after the call and remain accessible for 90 days on the investor relations website.